Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 14, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 625,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 14, 2012.
- Price Range: Highest price paid was 1,343.5 pence per share; lowest price paid was 1,327.0 pence per share.
- Treasury Holdings (Settled): 528,265,427 shares (9.70% of total issued share capital).
- Treasury Holdings (Including Unsettled): 530,140,427 shares (10.78% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,917,258,084 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 625,000 shares. Consequently, the percentage of total voting rights held in treasury increased to 10.78% when including unsettled purchases. The filing does not provide comparative financial data to assess material changes in operating performance versus prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (528,265,427 settled) against the latest public capitalization tables.
- Confirm the calculation of total voting rights (10.78% held in treasury including unsettled shares) for disclosure threshold assessments.
- Review the price paid (1,327.0 to 1,343.5 pence) against the market price on November 14, 2012, to assess execution efficiency.
- Note that this filing does not contain operational or financial performance metrics; refer to the most recent Form 20-F or quarterly results for those data points.